Investigational senolytic drug combination · Fact sheet
Dasatinib plus quercetin
Also known as D+Q · DQ senolytic combination
Dasatinib plus quercetin is not FDA approved for aging, frailty, fibrosis, kidney disease, or cognitive decline. Early pilot studies show feasibility and biomarker effects—not proven clinical benefit—and dasatinib has serious labeled toxicities.
What is Dasatinib plus quercetin?
Dasatinib is an FDA-approved kinase inhibitor for specific leukemias; quercetin is a plant flavonoid sold in supplements.
Researchers combine them because different senescent cell types may rely on different survival pathways. The experimental combination is a new claim set, not an extension of dasatinib's cancer approval.
Benefits people look for
Small studies in diabetic kidney disease and idiopathic pulmonary fibrosis reported changes in senescence markers or feasibility outcomes.
The approach directly tests a central geroscience hypothesis, but the human studies are far too small to establish improved disease or longevity outcomes.
What the evidence supports
- A small diabetic-kidney-disease study reported lower senescent-cell markers after treatment.
- Pulmonary-fibrosis pilots established feasibility but were not designed to prove disease modification.
All research areas
- Cellular senescence
- Idiopathic pulmonary fibrosis
- Diabetic kidney disease
- Frailty and aging biomarkers
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Dasatinib labeling describes myelosuppression, bleeding, fluid retention, cardiovascular effects, pulmonary arterial hypertension, severe skin reactions, and major interaction risks.
- Quercetin can add interaction and product-quality uncertainty.
- Intermittent research exposure does not erase the serious pharmacology of an oncology medicine.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceHuman evidence consists of small pilot studies focused on feasibility, safety, physical measures, and senescence biomarkers. There is no adequate trial showing fewer diseases, sustained functional benefit, or longer life.
Selected research to read
Very small open-label human study of senescence markers rather than clinical efficacy.
Small feasibility and tolerability study not powered for disease benefit.
Open-label pilot with no placebo comparison and major interpretive limits.
FDA approval & research status
The D+Q combination has no FDA-approved senolytic or geroscience use. Dasatinib alone is FDA approved for specific leukemia indications under prescription labeling.
No FDA-approved use is documented in the records summarized on this page.
Small clinical pilots, no approved senolytic use
Dasatinib alone is FDA approved for leukemia indications, but the dasatinib-plus-quercetin senolytic claim remains in small pilot research rather than a defined FDA approval path.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether senescence-marker changes improve any patient-centered outcome
- Which senescent cell types are affected in each human tissue
- Whether benefits could outweigh cancer-drug risks in people without cancer
- Long-term and repeated-course safety
The takeaway
D+Q is important proof-of-concept geroscience, not an established anti-aging treatment. The presence of an approved cancer drug makes casual wellness framing especially unsafe.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Sprycel
Dasatinib's approved cancer uses, warnings, adverse reactions, and interactions.
- 2pubmedD+Q diabetic kidney disease pilot
Very small open-label human study of senescence markers rather than clinical efficacy.
- 3pubmedRandomized D+Q pulmonary-fibrosis pilot
Small feasibility and tolerability study not powered for disease benefit.
- 4pubmedFirst-in-human D+Q pulmonary-fibrosis pilot
Open-label pilot with no placebo comparison and major interpretive limits.